Rowshanravan, B;
Halliday, N;
Sansom, DM;
(2018)
CTLA-4: a moving target in immunotherapy.
Blood
, 131
(1)
pp. 58-67.
10.1182/blood-2017-06-741033.
Preview |
Text
Rowshanravan, Halliday & Sansom, Blood, 2017.pdf - Accepted Version Download (2MB) | Preview |
Abstract
CD28 and CTLA-4 are members of a family of Immunoglobulin-related receptors that are responsible for various aspects of T cell immune regulation. The family includes CD28, CTLA-4 and ICOS as well as other proteins including PD-1, BTLA and TIGIT. These receptors have both stimulatory (CD28, ICOS) as well as inhibitory roles (CTLA-4, PD-1, BTLA and TIGIT) in T cell function. Increasingly these pathways are targeted as part of immune modulatory strategies to treat cancers, referred to generically as immune checkpoint blockade, and conversely to treat autoimmunity and CTLA-4 deficiency. Here we focus on the biology of the CD28/CTLA-4 pathway as a framework for understanding the impacts of therapeutic manipulation of this pathway.
Archive Staff Only
 |
View Item |
